FDA Class II Recall Affects 3,744 Bottles of Generic Blood Pressure Medication

Key points

• Macleods Pharma USA initiated a voluntary recall on October 7, 2026, for two lots of combination blood pressure tablets.
• The FDA classified the recall as Class II on October 26, 2026, indicating potential temporary adverse health consequences but a remote likelihood of serious harm.
• The recall covers 3,528 bottles of 30-count packages (Lot 12251163A) and 216 bottles of 90-count packages (Lot 12251163B), both expiring on May 31, 2027.
• The medication failed dissolution testing, a quality standard ensuring pills break down and release active ingredients correctly in the body.
• The recalled generic version is equivalent to brand-name drugs Tribenzor and Benicar HCT, but the FDA has not issued recalls for the brand-name versions.
• Patients are advised to continue taking the medication unless directed otherwise by a healthcare provider, as abrupt discontinuation can be dangerous.

Background

This recall follows a pattern of recent FDA actions regarding blood pressure medications. In September 2026, the FDA classified a recall of 13,567 bottles of chlorthalidone tablets by Inventia Healthcare Ltd. as Class II after they failed dissolution tests. This was the second recall for that specific medication and manufacturer in three months. Additionally, in October 2026, the FDA issued a recall for Viatris telmisartan tablets. These events highlight ongoing scrutiny of dissolution quality in generic hypertension medications.

How outlets are covering it

All four sources (Yahoo News, Fox Business, WMUR, and Newsday) agree on the core facts: the manufacturer (Macleods Pharma USA), the specific drug combination, the lot numbers, the Class II classification, and the reason for the recall (failed dissolution). Fox Business and Newsday provide additional detail on the National Drug Codes (NDCs) for identification. Newsday notes that the recalled generic is equivalent to brand-name Tribenzor and Benicar HCT, clarifying that brand-name versions are not affected. WMUR and Fox Business mention the recent chlorthalidone recall as context, emphasizing a trend in dissolution failures. No source reports on patient harm or specific side effects, consistent with the FDA's Class II definition of remote serious consequences.

Why it matters

The recall affects thousands of patients nationwide who rely on this combination medication to manage high blood pressure, a key risk factor for heart attack and stroke. While the FDA deems serious harm unlikely, the failure of dissolution specifications means the medication may be ineffective, potentially leaving patients with uncontrolled blood pressure. The Class II classification underscores the importance of patient vigilance and adherence to medical advice, as stopping the medication abruptly can be more dangerous than taking a potentially ineffective pill. This incident also highlights the FDA's ongoing monitoring of generic drug quality, particularly dissolution testing, which is critical for ensuring therapeutic equivalence with brand-name drugs.

What to watch

Macleods Pharma USA is responsible for managing the recall, including notifying distributors and ensuring replacement products are available. Patients with affected lot numbers should contact their pharmacists or healthcare providers to arrange for replacement medication. The FDA will continue to monitor the recall's progress and may update its status if new information emerges. No further action is expected from the FDA unless the recall is not completed satisfactorily or if adverse events are reported.